×
Galecto Common Stock Net 2020-2025 | GLTO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Galecto common stock net from 2020 to 2025. Common stock net can be defined as the value of common equity ownership.
View More
Galecto Common Stock Net 2020-2025 | GLTO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Galecto common stock net from 2020 to 2025. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$228.1B
Amgen (AMGN)
$155.2B
Gilead Sciences (GILD)
$148.5B
Vertex Pharmaceuticals (VRTX)
$94B
Bristol Myers Squibb (BMY)
$93.5B
CSL (CSLLY)
$82.7B
GSK (GSK)
$77.1B
Regeneron Pharmaceuticals (REGN)
$60.8B
Alnylam Pharmaceuticals (ALNY)
$57.5B
Argenex SE (ARGX)
$40.5B
BioNTech SE (BNTX)
$26.8B
Royalty Pharma (RPRX)
$21.1B
Insmed (INSM)
$20.8B
Biogen (BIIB)
$19.2B
Incyte (INCY)
$15.3B
Illumina (ILMN)
$14.5B
Genmab (GNMSF)
$14.3B
Genmab (GMAB)
$13.7B
Ascendis Pharma (ASND)
$11.7B
BioMarin Pharmaceutical (BMRN)
$11B
QIAGEN (QGEN)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Moderna (MRNA)
$10.2B
Exelixis (EXEL)
$10.2B
Verona Pharma American Depositary Share (VRNA)
$9B
Blueprint Medicines (BPMC)
$8.3B
Bio-Techne Corp (TECH)
$7.9B
Roivant Sciences (ROIV)
$7.8B
Exact Sciences (EXAS)
$7.8B
Halozyme Therapeutics (HALO)
$7.8B